Mithramycin depletes specificity protein 1 and activates p53 to mediate senescence and apoptosis of malignant pleural mesothelioma cells

Clinical Cancer Research

Volumn 22, Issue 5, 2016, Pages 1197-1210

  Rao, Mahadev ^a   Atay, Scott M ^a   Shukla, Vivek ^a   Hong, Young ^a   Upham, Trevor ^a   Ripley, R Taylor ^a   Hong, Julie A ^a   Zhang, Mary ^a   Reardon, Emily ^a   Fetsch, Patricia ^a   Miettinen, Markku ^a   Li, Xinmin ^b   Peer, Cody J ^a   Sissung, Tristan ^a   Figg, William D ^a   De Rienzo, Assunta ^c   Bueno, Raphael ^c   Schrump, David S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; MITHRAMYCIN; PROTEIN P53; TRANSCRIPTION FACTOR SP1; SP1 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GROWTH; CELL CYCLE REGULATION; CELL MIGRATION; CELL PROLIFERATION; CHEMOTAXIS; CHROMATIN IMMUNOPRECIPITATION; CLONOGENESIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MESOTHELIUM CELL; MICROARRAY ANALYSIS; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; ONCOGENE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENESCENCE; SIGNAL TRANSDUCTION; TUMOR XENOGRAFT; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL AGING; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; MESOTHELIOMA; MIDDLE AGED; PATHOLOGY; PLEURAL NEOPLASMS;

ANIMALS; APOPTOSIS; BIOMARKERS, TUMOR; CELL AGING; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MESOTHELIOMA; MICE; MIDDLE AGED; PLEURAL NEOPLASMS; PLICAMYCIN; RNA, MESSENGER; SP1 TRANSCRIPTION FACTOR; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84962264656     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-14-3379     Document Type: Article

References (50)

1. Bononi A, Napolitano A, Pass HI, Yang H, Carbone M. Latest developments in our understanding of the pathogenesis of mesothelioma and the design of targeted therapies. Expert Rev Respir Med 2015;9:633-54.
2. Carbone M, Baris YI, Bertino P, Brass B, Comertpay S, Dogan AU, et al. Erionite exposure in North Dakota and Turkish villages with mesothelioma. Proc Natl Acad Sci USA 2011;108:13618-23.
3. International Agency for Research on Cancer. IARC monographs on the evaluation of carcinogenic risks of humans: Volume 100C: a review of human carcinogens: arsenic, metals, fibres, and dust. Lyon, France: International Agency for Research on Cancer; 2011.
4. Henley SJ, Larson TC, Wu M, Antao VC, Lewis M, Pinheiro GA, et al. Mesothelioma incidence in 50 states and the District of Columbia, United States, 2003-2008. Int J Occup Environ Health 2013;19:1-10.
5. Leuzzi G, Rea F, Spaggiari L, Marulli G, Sperduti I, Alessandrini G, et al. Prognostic score of long-term survival after surgery for malignant pleural mesothelioma: a multicenter analysis. Ann Thorac Surg 2015; 100:890-7.
6. Opitz I, Friess M, Kestenholz P, Schneiter D, Frauenfelder T, Nguyen- Kim DL, et al. A new prognostic score supporting treatment allocation for multimodality therapy for malignant pleural mesothelioma- A review of 12 years' experience. J Thorac Oncol. 2015 Aug 27. [Epub ahead of print].
7. Shersher DD, Liptay MJ. Multimodality treatment of pleural mesothelioma. Surg Oncol Clin N Am 2013;22:345-55.
8. Bott M, Brevet M, Taylor BS, Shimizu S, Ito T, Wang L, et al. The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet 2011;43: 668-72.
9. Nasu M, Emi M, Pastorino S, Tanji M, Powers A, Luk H, et al. High incidence of somatic BAP1 alterations in sporadicmalignantmesothelioma. J Thorac Oncol 2015;10:565-76.
10. Testa JR, Cheung M, Pei J, Below JE, Tan Y, Sementino E, et al. Germline BAP1 mutations predispose to malignant mesothelioma. Nat Genetics 2011;43:1022-1025.
11. Scheuermann JC, de Ayala Alonso AG, Oktaba K, Ly-Hartig N, McGinty RK, Fraterman S, et al. Histone H2A deubiquitinase activity of the Polycomb repressive complex PR-DUB. Nature 2010;465:243-7.
12. Jean D, Daubriac J, Le Pimpec-Barthes F, Galateau-Salle F, Jaurand MC. Molecular changes in mesothelioma with an impact on prognosis and treatment. Arch Pathol Lab Med 2012;136:277-93.
13. Riquelme E, Suraokar MB, Rodriguez J, Mino B, Lin HY, Rice DC, et al. Frequent coamplification and cooperation between C-MYC and PVT1 oncogenes promote malignant pleural mesothelioma. J Thorac Oncol 2014;9:998-1007.
14. Kemp CD, Rao M, Xi S, Inchauste S, Mani H, Fetsch P, et al. Polycomb repressor complex-2 is a novel target for mesothelioma therapy. Clin Cancer Res 2012;18:77-90.
15. Kubo T, Toyooka S, Tsukuda K, Sakaguchi M, Fukazawa T, Soh J, et al. Epigenetic silencing of microRNA-34b/c plays an important role in the pathogenesis of malignant pleural mesothelioma. Clin Cancer Res 2011;17:4965-74.
16. Christoph DC, Eberhardt WE. Systemic treatment of malignant pleural mesothelioma: new agents in clinical trials raise hope of relevant improvements. Curr Opin Oncol 2014;26:171-81.
17. Blume SW, Snyder RC, Ray R, Thomas S, Koller CA, Miller DM. Mithramycin inhibits SP1 binding and selectively inhibits transcriptional activity of the dihydrofolate reductase gene in vitro and in vivo. J Clin Invest 1991;88:1613-21.
18. Li L, Davie JR. The role of Sp1 and Sp3 in normal and cancer cell biology. Ann Anat 2010;192:275-83.
19. Safe S, Imanirad P, Sreevalsan S, Nair V, Jutooru I. Transcription factor Sp1, also known as specificity protein 1 as a therapeutic target. Expert Opin Ther Targets 2014;18:759-69.
20. Davie JR, He S, Li L, Sekhavat A, Espino P, Drobic B, et al. Nuclear organization and chromatin dynamics-Sp1, Sp3 and histone deacetylases. Adv Enzyme Regul 2008;48:189-208.
21. Zhang M, Mathur A, Zhang Y, Xi S, Atay S, Hong JA, et al. Mithramycin represses basal and cigarette smoke-induced expression of ABCG2 and inhibits stem cell signaling in lung and esophageal cancer cells. Cancer Res 2012;72:4178-92.
22. Saha S, Mukherjee S, Mazumdar M, Manna A, Khan P, Adhikary A, et al. Mithramycin A sensitizes therapy-resistant breast cancer stem cells toward genotoxic drug doxorubicin. Transl Res 2015;165:558-77.
23. Chen DQ, Huang JY, Feng B, Pan BZ, De W, Wang R, et al. Histone deacetylase 1/Sp1/microRNA-200b signaling accounts for maintenance of cancer stem-like cells in human lung adenocarcinoma. PLoS One 2014;9:e109578.
24. Yang WJ, Song MJ, Park EY, Lee JJ, Park JH, Park K, et al. Transcription factors Sp1 and Sp3 regulate expression of human ABCG2 gene and chemoresistance phenotype. Mol Cells 2013;36:368-75.
25. Aarskog NK, Vedeler CA. Real-time quantitative polymerase chain reaction. A new method that detects both the peripheral myelin protein 22 duplication in Charcot-Marie-Tooth type 1A disease and the peripheral myelin protein 22 deletion in hereditary neuropathy with liability to pressure palsies. Hum Genet 2000;107:494-8.
26. Rao M, Chinnasamy N, Hong JA, Zhang Y, Zhang M, Xi S, et al. Inhibition of histone lysine methylation enhances cancer-testis antigen expression in lung cancer cells: implications for adoptive immunotherapy of cancer. Cancer Res 2011;71:4192-204.
27. Thenappan A, Shukla V, Abdul Khalek FJ, Li Y, Shetty K, Liu P, et al. Loss of transforming growth factor beta adaptor protein beta-2 spectrin leads to delayed liver regeneration in mice. Hepatology 2011;53:1641-50.
28. Jami MS, Hou J, Liu M, Varney ML, Hassan H, Dong J, et al. Functional proteomic analysis reveals the involvement of KIAA1199 in breast cancer growth, motility and invasiveness. BMC Cancer 2014;14:194.
29. Evensen NA, Kuscu C, Nguyen HL, Zarrabi K, Dufour A, Kadam P, et al. Unraveling the role of KIAA1199, a novel endoplasmic reticulum protein, in cancer cell migration. J Natl Cancer Inst 2013;105:1402-16.
30. Meigs TE, Fields TA, McKee DD, Casey PJ. Interaction of Galpha 12 and Galpha 13 with the cytoplasmic domain of cadherin provides a mechanism for beta -catenin release. Proc Natl Acad Sci U S A 2001;98: 519-24.
31. Tang H, Wei P, Duell EJ, Risch HA, Olson SH, Bueno-de-Mesquita HB, et al. Axonal guidance signaling pathway interactingwith smoking inmodifying the risk of pancreatic cancer: a gene- and pathway-based interaction analysis of GWAS data. Carcinogenesis 2014;35:1039-45.
32. Liu F, Pore N, Kim M, Voong KR, Dowling M, Maity A, et al. Regulation of histone deacetylase 4 expression by the SP family of transcription factors. Mol Biol Cell 2006;17:585-97.
33. Marouco D, Garabadgiu AV, Melino G, Barlev NA. Lysine-specific modifications of p53: a matter of life and death? Oncotarget 2013;4: 1556-71.
34. Sun Z, Wang L, Eckloff BW, Deng B, Wang Y, Wampfler JA, et al. Conserved recurrent gene mutations correlate with pathway deregulation and clinical outcomes of lung adenocarcinoma in never-smokers. BMC Med Genomics 2014;7:32.
35. Cao HH, Zheng CP, Wang SH, Wu JY, Shen JH, Xu XE, et al. A molecular prognostic model predicts esophageal squamous cell carcinoma prognosis. PLoS One 2014;9:e106007.
36. Curreri AR, Ansfield FJ. Mithramycin-human toxicology and preliminary therapeutic investigation. Cancer Chemother Rep 1960;8:18-22.
37. Sewell IA, Ellis H. A trial of mithramycin in the treatment of advanced malignant disease. Br J Cancer 1966;20:256-63.
38. Ohgami T, Kato K, Kobayashi H, Sonoda K, Inoue T, Yamaguchi S, et al. Low-dose mithramycin exerts its anticancer effect via the p53 signaling pathway and synergizes with nutlin-3 in gynecologic cancers. Cancer Sci 2010;101:1387-95.
39. Zhao Y, Zhang W, Guo Z, Ma F, Wu Y, Bai Y, et al. Inhibition of the transcription factor Sp1 suppresses colon cancer stem cell growth and induces apoptosis in vitro and in nude mouse xenografts. Oncol Rep 2013;30:1782-92.
40. Choi ES, Chung T, Kim JS, Lee H, Kwon KH, Cho NP, et al. Mithramycin A induces apoptosis by regulating the mTOR/Mcl-1/tBid pathway in androgen- independent prostate cancer cells. J Clin Biochem Nutr 2013;53:89-93.
41. Otjacques E, Binsfeld M, Rocks N, Blacher S, Vanderkerken K, Noel A, et al. Mithramycin exerts an anti-myeloma effect and displays anti-angiogenic effects through up-regulation of anti-angiogenic factors. PLoS One 2013;8: e62818.
42. Enge M, Bao W, Hedstrom E, Jackson SP, Moumen A, Selivanova G. MDM2-dependent downregulation of p21 and hnRNP K provides a switch between apoptosis and growth arrest induced by pharmacologically activated p53. Cancer Cell 2009;15:171-83.
43. Li H, Zhang Y, Strose A, Tedesco D, Gurova K, Selivanova G. Integrated high-throughput analysis identifies Sp1 as a crucial determinant of p53- mediated apoptosis. Cell Death Differ 2014;21:1493-502.
44. Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer 2013;13:83-96.
45. Lin RK, Wu CY, Chang JW, Juan LJ, Hsu HS, Chen CY, et al. Dysregulation of p53/Sp1 control leads to DNA methyltransferase-1 overexpression in lung cancer. Cancer Res 2010;70:5807-17.
46. Banerjee A, Sanyal S, Kulkarni KK, Jana K, Roy S, Das C, et al. Anticancer drug mithramycin interacts with core histones: An additional mode of action of the DNA groove binder. FEBS Open Bio 2014;4:987-95.
47. Zhang B, Golding BT, Hardcastle IR. Small-molecule MDM2-p53 inhibitors: recent advances. Future Med Chem 2015;7:631-45.
48. Nguyen DM, Schrump WD, Chen GA, Tsai W, Nguyen P, Trepel JB, et al. Abrogation of p21 expression by flavopiridol enhances depsipeptidemediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res 2004;10:1813-25.
49. Roth J, Peer CJ, Widemann B, Cole DE, Ershler R, Helman L, et al. Quantitative determination of mithramycin in human plasma by a novel, sensitive ultra-HPLC-MS/MS method for clinical pharmacokinetic application. J Chromatogr B Analyt Technol Biomed Life Sci 2014;970:95-101.
50. Kennedy BJ, Sandberg-Wollheim M, Loken M, Yarbro JW. Studies with tritiated mithramycin in C3H mice. Cancer Res 1967;27: 1534-8.